Cross-talk between ER and HER2 in breast carcinoma

Archive of Oncology

Volumn 14, Issue 3-4, 2006, Pages 146-150

  Todorović Raković, Nataša ^a   Nešković Konstantinović, Zora ^a   Nikolić Vukosavljević, Dragica ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Breast neoplasms; Receptor cross talk; Receptor, epidermal growth factor; Receptor, erbB 2; Receptors, estrogen

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; TAMOXIFEN;

BREAST CARCINOMA; CANCER GROWTH; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; PATHOGENESIS; PROTEIN INTERACTION; REVIEW;

EID: 34147105901     PISSN: 03547310     EISSN: None     Source Type: Journal    
DOI: 10.2298/AOO0604146T     Document Type: Review

References (48)

1. Gruvberger S, Ringer M, Chen Y, Panavally S, Saal LH, Borg A, et al. Estrogen receptor status iin breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-84.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
3. McGuire WL. Steroid hormone receptors in breast cancer treatment strategy. Rec Prog Horm Res 1980;36:135-6.
4. nd ed. Philadelphia: Lippincot Williams & Wilkins; 2000. p. 471-88.
5. Benz CC. HER2 and endocrine response in breast cancer. Oncology Exchange 2004;3:8-11.
6. Eppenberger-Castori S, Kueng W, Benz C, Caduff R, Varga Z, Bannwart F, et al. Prognostic and predictive significance of Erb-B2 breast tumor levels measured bay enzyme immunoassay. J Clin Oncol 2001;19:645-6.
7. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, et al. Estrogen dependent tamoxifen-resistanttumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992;24:85-95.
8. Katzenellbogen JA, Katzenellbogen BS, nuclear hormone receptors: ligand-activatedregulators of transcription and diverse cell responses. Chem Biol 1996;3:529-36.
9. Nilsen N, Makel S, Treutert E, Tujague M, Thomsen J, Anderson G, et al. Mechanisms of estrogen action. Phys Rev 2001;81:1536-65.
10. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-83.
11. Kato S, Endooh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
12. Sarwar N, Kim J-S, Jiang J, Peston D, Sinett HD, Madden P, et al. phosphorzlation of ER alpha in primary breast cancer and in tamoxifen-resiastant tumors is indicative of a comlex role for ER alpha phosphorylation in breast cancer progression. End Rel Cancer 2006;13:851-6.
13. Normano N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. End Rel Cancer 2005;12:721-47.
14. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Stem Cells 1998;16:413-28
15. Wilson KS, Roberts H, Leek R, Harris AL, Geradts J. Differential gene expression patterns in HER2/neu positive and negative breast cancer cell lines and tissues. Am J Pathol 2002;161:1171-85.
16. Rubin I, Yarden Y, The basic biology of HER2. Ann Oncol 2001,12:S3-S8.
17. Nagy P, Jenel A, Damjanovich S, Jovin TM, Szollosi J. Complexity of signal transduction mediated by ErbB2:clues to the potential of receptor-targeted cancer therapy. Path Oncol Res 1999;5:256-70.
18. Hynes NF, Stern DF. The biology of erbB-2/neu/HER2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
19. Schiff R, Massarwech SA, Shou J, Bharwani L, Mohsin IK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathawys as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2000;10:331s-36s.
20. Campbell RA, Bhat-Nakshatri P, Patel Constantinidou D, Ali S Nakshatri H. Phosphatidylinositol 3- kinase/AKT - mediated activation of estrogen receptor aphas: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
21. Chisamore M, Ahmed Y, Bentrem DJ, Jordan VC, Toneti DA. Novel antitumor effect of estradiol in athymic mice injected with T47D breast cancefr cell line overexpressing protein kinase C alpha. Clin Cancer Res 2001;7:3156-65.
22. Parisot JP, Hu XF, deLuse M Zalcberg JR. Altered expression of the IGF-1 receptor in a tamoxifen-resiastant breast cancer cell line. Br J Cancer 1999;79:693-700.
23. Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Kruptza G, et al. Bidirectional interaction between the estrogen receptor and the erbB-2 signaling pathways:heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer.1995;63:560-7.
24. Stoica GE, Franke TF, Wellstein A, Morgan E, Czubayko F, List HJ, et al. Heregulin-betal regulates the estrogen receptor alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene 2003;22:2073-87.
25. Mazumdar A,Wang RA, Mishra SK, Adam L, Bagheri-Varmand R, Mandal M, et al. Transcriptional repression of estrogen receptor by metastasis-associated protein 1 compressor. Nat Cell Biol 2000;3:30-7.
26. Osborne CK, Schiff R. Estrogen receptor biology: continuing progress and therapeutic implications. J Clin Oncology 2005;23:1616-22.
27. Stoica A, Saceda M, Doariswamy VL, Coleman C, Martin MB. Regulation of estogen receptor-alpha gene expression by epidermal growth factor. J Endocrinol 2000; 165:371-8.
28. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al. HER2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;9:2435-46.
29. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 2000;9:490-7.
30. Konecny G, Pauletti G, Pegram M, Unich M, Dandekar S, Aguilar Z, et al. Quantitative association between HER2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
31. Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER2 gene independent of epidermal growth factor receptor. Oncogene 1992;7:1859-66.
32. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M Dixon M, et al. HER2 amplification impedes antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001;61:8452-8.
33. Gutierrez CM, Detre S, Johnston S, Mohsin SK, Shou J, Allred CD, et al. Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase J Clin Oncol 2005;23.2469-76.
34. Kun Y, How LC, Hoon TP, Bajič VB, Lam TS, Aggarwai A, et al. Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Hum Mol Genetics 2003;12:3245-58.
35. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK. Her2 amplication, HER1 expression and tamoxifen response in estrogen receptor-positive metatstic breast camera southwest oncology group study. Clin Cancer Res 2004;10:5670-6.
36. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997;99:1478-83.
37. Oh A, Lorant LA, Holloway JN, Miller DL, Kern FG, El-ashry D. Hyperactivation of MAPK induces loss of ER expression in breast cancer cells. Mol Endocrinology 2001;15:1344-59.
38. Kurokawa H, Lenferink AEG, Simpson JF, Pisacane PI, Sliwkowski MX, Fortes JT et al. Inhibition of HER2/neu (erbB-2) and Mitogen-activated Protein Kinases Enhances Tamoxifen Action against HER2-overexpressing, Tamoxifen-resistarrt Breast Cancer Cells. Cancer Res 2000;60:5887-94.
39. Horwitz KB, Jackson TA, Bain D, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinology 1996;10:1167-77.
40. List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT, et al. Ribozyme targeting demonstrates that the nuclear receptor coactivator A1B1 is a rate limiting factor for estrogen dependent growth of human MCF-7 breast cancer cells. J Biol Chem 2001;276:23763-8.
41. Bouras T, Southey MC, Venter DJ. Overexpresskm of the steroid receptor coactivatotr A1B1 in breast cancer correlates with the absence of estrogen and progesteron receptors and posistivity for p53 and HER27neu. Cancer Res 2001;61:903-7.
42. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck GC, Fuqua SA, et al. Role of the estrogen receptor coactivator A1B1 (SRC-3) and HER2-/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
43. Font de Mora J, Brown M. A1B1 is conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20:5041-7.
44. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-70s.
45. Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. The Breast 2005;14:458-65.
46. Yang Z, Barnes C, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 2004;10:3621-8.
47. Chung YI, Sheu ML, Yang SC, Lin CH, Yen SH. Resistance to tamoxifen-induced apoptosis is associated with directs interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002;97:306-12.
48. Henry LN, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring and treatment of primary and metastatic breast cancer. The Oncologist 2006;11:541-52.